E. Yoosakul, “Comparative Randomized, Single Dose, Two-Way Crossover, Open-Label Study to Determine the Bioequivalence of Irbesartan Formulation, Irbesartan GPO 150 mg Tablets and Aprovel® 150 mg Tablets, after Oral Administration to Healthy Thai Volunteers under Fasti”, J Health Res, vol. 30, no. 3, pp. 199–205, Feb. 2017.